Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.